FDA Grants Breakthrough Status to Novel Breast Cancer Drug Zovegalisib

CAMBRIDGE, Mass. – February 03, 2026 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to zovegalisib, an investigational cancer drug from Relay Therapeutics, signaling a potentially significant advancement for thousands of patients with a common and difficult-to-treat form of advanced breast cancer. The designation, announced today, is for the use of zovegalisib in combination with the endocrine therapy fulvestrant and is aimed at patients whose disease has progressed despite treatment with current standard-of-care therapies.

The decision fast-tracks the development and review of zovegalisib for adults with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer that harbors a PIK3CA mutation. This specific genetic mutation is found in approximately 40% of patients with this breast cancer subtype and is associated with poorer prognoses and resistance to treatment. The FDA’s designation acknowledges the drug's potential to provide a substantial improvement over available therapies for this high-need population.

“This Breakthrough Therapy designation underscores the FDA’s recognition of the potential of zovegalisib in combination with fulvestrant to meaningfully improve outcomes for these patients,” said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics, in a statement. He noted that the designation reinforces the “encouraging clinical evidence” demonstrated to date.

Addressing a Critical Unmet Need

The current treatment journey for patients with HR+/HER2- advanced breast cancer typically begins with a combination of endocrine therapy and a CDK4/6 inhibitor. While this regimen has significantly improved outcomes, resistance is nearly inevitable, forcing patients and their doctors to seek next-line options. For those with a PIK3CA mutation, the approved path often involves a PI3K inhibitor, but existing options have been hampered by significant side effects.

The first generation of PI3K inhibitors, while effective for some, can cause high rates of severe hyperglycemia, rash, diarrhea, and mouth sores. These toxicities stem from the drugs' mechanism, which inhibits both the mutant cancer-driving protein and its healthy, wild-type counterpart that regulates normal cellular functions like glucose metabolism. The side effects are often so severe that they lead to dose reductions or treatment discontinuation, limiting the drugs' overall benefit.

Patient advocacy forums reflect this struggle, with individuals sharing experiences of debilitating side effects that compromise their quality of life. The prospect of a therapy that can control the cancer with fewer of these adverse events is a source of considerable hope.

Zovegalisib was designed specifically to overcome this challenge. It represents a new class of highly selective inhibitors that can distinguish between the mutant and wild-type forms of the PI3Kα protein. This precision targeting is intended to shut down the cancer-driving pathway while leaving the normal pathway largely untouched, thereby minimizing collateral damage and improving tolerability.

The Science of Selective Inhibition

Zovegalisib is the lead product to emerge from Relay Therapeutics' proprietary Dynamo® platform, which integrates advanced computational physics and experimental biology to understand protein motion and design drugs against previously intractable targets. The company developed zovegalisib as the first known “allosteric, pan-mutant, and isoform-selective” PI3Kα inhibitor.

Unlike traditional “orthosteric” inhibitors that bind to the protein’s active site—a region shared by both mutant and wild-type forms—zovegalisib binds to an allosteric pocket, a secondary site present only when the protein is in its mutated, cancer-causing conformation. This novel mechanism allows it to selectively neutralize a wide range of PIK3CA mutations while sparing the healthy protein, a breakthrough in precision oncology.

The clinical data supporting the Breakthrough Therapy Designation comes from the Phase 1/2 ReDiscover trial. Results presented at major oncology conferences in 2025 painted a compelling picture. In a cohort of 52 heavily pre-treated patients, zovegalisib in combination with fulvestrant demonstrated a median progression-free survival (PFS) of 9.2 months. For patients receiving it as a second-line therapy, the median PFS extended to 11.4 months.

Crucially, the safety profile appeared markedly improved over existing PI3K inhibitors. Rates of Grade 3 (severe) hyperglycemia were just 2.5%, and severe diarrhea was 1.7%. Other common side effects like rash and stomatitis were rare, and no life-threatening (Grade 4 or 5) treatment-related adverse events were reported. This favorable safety profile suggests that patients may be able to stay on therapy longer, potentially leading to better long-term disease control.

“The lower incidence of high-grade toxicities is what makes us very enthusiastic,” commented one leading oncologist not involved with the study. “If we can deliver the efficacy of PI3K inhibition without the challenging side effects, it would represent a paradigm shift in how we manage this disease.”

The Path Forward and Market Implications

Breakthrough Therapy Designation is more than a commendation; it is a powerful accelerator. The program provides Relay Therapeutics with more intensive FDA guidance, eligibility for rolling review of its marketing application, and the potential for a shorter path to approval. Historically, drugs with this designation can reach patients two to three years faster than those on a standard timeline.

Investor and analyst sentiment has been overwhelmingly positive, with the designation seen as a major de-risking event for both zovegalisib and Relay's underlying Dynamo platform. With a potential target population of approximately 140,000 patients annually in the United States, analysts project peak sales for zovegalisib could exceed $1 billion, positioning it as a major contender in the multi-billion-dollar breast cancer market.

All eyes are now on the next set of clinical milestones. Relay is scheduled to present the first data from the 400mg twice-daily fed dose—the official dose being used in the pivotal Phase 3 trial—at the upcoming ESMO Targeted Anticancer Therapies Congress on March 16. This dose was selected in part based on feedback from patient advocates for a more patient-friendly regimen that does not require fasting.

The ongoing Phase 3 ReDiscover-2 trial will provide the ultimate test, as it is designed to compare zovegalisib directly against another approved PI3K pathway inhibitor in this patient population. Success in this head-to-head study would not only confirm the drug's promising early results but could firmly establish it as a new, superior standard of care, offering a powerful combination of efficacy and tolerability for patients in critical need of better options.